Company intelligence / Profile preview

Firefly Photography

South San Francisco, California, United Stateswhimsicalstorytelling.com ↗

Ownership: Private
Development stage: Other

Overview

Firefly Bio has developed a novel preclinical platform for treating cancer using degrader antibody conjugates. This approach aims to combine the cell-targeting specificity of ADCs with the catalytic protein knockdown ability of degraders. The company emerged from stealth in February 2024 with $94 million Series A financing and has selected its lead asset but has not yet entered clinical trials.

Therapeutic areas: Oncology
Modalities: Degrader antibody conjugate therapyAntibody-drug conjugate (as a component of their platform)Protein degrader therapy (as a component of their platform)
Industry: Biotech

Partnerships

Versant Ventures (founding investor)MPM BioImpact (investor)Decheng Capital (investor)Eli Lilly & Company (investor/partner)

Beyond the preview

Go deeper on Firefly Photography.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Firefly Photography.

Explore the full profile